CERo Therapeutics Holdings, Inc. (CERO)

CERO Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	4.59	1.6	6.82	19.22
Cash & Cash Equivalents	4.59	1.6	6.82	19.22
Cash Growth	186.84%	-76.52%	-64.51%	-
Receivables	0.16	0	0	0
Other Current Assets	0.75	0.37	0.26	0.31
Total Current Assets	5.5	1.97	7.08	19.52
Property, Plant & Equipment	2.87	3.16	4.27	4.65
Other Long-Term Assets	0.68	0	0	0
Total Long-Term Assets	3.55	3.16	4.27	4.65
Total Assets	9.05	5.13	11.35	24.18
Accounts Payable	7.06	1.67	0.39	0.46
Current Debt	1.2	1.37	0.67	0.59
Other Current Liabilities	3.39	0.47	0.1	0.79
Total Current Liabilities	11.65	3.51	1.16	1.84
Long-Term Debt	1.38	1.58	2.34	3.02
Other Long-Term Liabilities	0	0	0.61	0.65
Total Long-Term Liabilities	1.38	1.58	2.95	3.66
Total Liabilities	13.03	5.08	4.12	5.5
Total Debt	2.58	2.94	3.02	3.6
Debt Growth	-12.45%	-2.41%	-16.25%	-
Retained Earnings	-64.91	-43.09	-35.8	-23.97
Shareholders' Equity	-3.98	-42.06	-34.87	-23.43
Net Cash / Debt	2.02	-1.34	3.8	15.62
Net Cash / Debt Growth	-	-	-75.65%	-
Net Cash Per Share	-	-0.15	0.42	1.74
Working Capital	-6.15	-1.54	5.91	17.69
Book Value Per Share	-0.33	-4.64	-3.89	-2.61

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).